Prediction Case File
YouTubeEvaluation Complete

Looking for low-cost biotech opportunities with big upside? In this video, MarketBeat’s Chris Markoch breaks down 3 speculative biotech stocks trading under $5 — each with significant growth potential and analysts’ price targets far above their current share price.

2 extracted signals · 2 resolved · 0 still active

MarketBeat profile imageMarketBeat14 Sept 2025, 22:25 UTC
Video preview for Looking for low-cost biotech opportunities with big upside? In this video, MarketBeat’s Chris Markoch breaks down 3 speculative biotech stocks trading under $5 — each with significant growth potential and analysts’ price targets far above their current share price.
Signals
2
Eligible signals in this source
Open
0
Still being tracked
Resolved
2
Evaluable outcomes
Successful
0
Canonical correct result
Failed
2
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

The video presents a fundamental analysis of three biotech stocks under $5. It suggests Hoth Therapeutics (HOTH), currently at $1.60, could reach $4 per share, highlighting its oncology and weight loss drug candidates. The analysis also covers Silo Pharma (SILO), priced at $0.65, noting its partnership with Hoth in obesity treatments and cryptocurrency strategy to fund operations. Anixa Biosciences (ANIX), trading at $2.93, is mentioned for its CAR-T immunotherapy program, partnered with Moffitt Cancer Center and the Cleveland Clinic, setting a price target of $9 per share. It is emphasized that while these stocks carry risk, potential gains exist for long-term investors. A free article is offered for more information, alongside text alerts for stock updates.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

MarketBeat

Tracked signals
988
Historical success
42.8%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.